Aldeyra Therapeutics shares are trading higher. The company announced the clinical development plan intended to enable resubmission of a New Drug Application for reproxalap in dry eye disease.

Aldeyra Therapeutics, Inc. +2.50%

Aldeyra Therapeutics, Inc.

ALDX

3.48

+2.50%

Aldeyra Therapeutics shares are trading higher. The company announced the clinical development plan intended to enable resubmission of a New Drug Application for reproxalap in dry eye disease.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via